Changeflow GovPing Pharma & Drug Safety Health Canada Consults on Antimicrobial Drug CA...
Priority review Consultation Added Consultation

Health Canada Consults on Antimicrobial Drug CAN-AWaRe Classification

Favicon for www.canada.ca Canada Health Canada Drug Announcements
Published
Detected
Email

Summary

Health Canada has opened a 60-day public consultation on the proposed Canadian Access, Watch, Reserve (CAN-AWaRe) classification framework for antimicrobial drugs for human use. The consultation runs until June 8, 2026, and seeks feedback from healthcare professionals, industry, academia, and public health agencies on the proposed classification of antibacterial drugs. Comments will inform the finalization of the CAN-AWaRe framework.

What changed

Health Canada is proposing a CAN-AWaRe classification framework for antimicrobial drugs for human use, based on the WHO AWaRe model. The framework categorizes antibacterial drugs into Access, Watch, and Reserve categories to support antimicrobial stewardship. The 60-day public consultation seeks input from healthcare professionals, industry, academia, and public health agencies on the proposed classification of each listed antibacterial.

Pharmaceutical manufacturers and healthcare providers should review the proposed classifications and submit comments by June 8, 2026. This framework will influence antimicrobial stewardship policies, drug approval processes, and prescribing guidelines in Canada. Stakeholders are encouraged to provide evidence-based rationale for any alternative classifications recommended.

What to do next

  1. Review the proposed CAN-AWaRe classification for antimicrobial drugs
  2. Submit comments by June 8, 2026 via online questionnaire, email, or mail
  3. Provide rationale and supporting evidence for any disagreements with proposed classifications

Archived snapshot

Apr 9, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Consultation: Canadian Access, Watch, Reserve classification of antimicrobial drugs for human use

Current status: Open

Opened on April 9, 2026, and will close to new input on June 8, 2026.

Health Canada is seeking stakeholder feedback on the proposed Canadian Access, Watch, Reserve (CAN-AWaRe) classification of antimicrobial drugs for human use.

We will consider all comments received before finalizing the CAN-AWaRe classification.

Read the notice to learn more about the CAN-AWaRe classification.

Join in: How to participate

You can provide your feedback in the following ways:

Share your ideas online

Complete the online questionnaire to submit your comments.

Send us an email

Send an email to amr-ram@hc-sc.gc.ca with your ideas or comments to make yourself heard.

Participate by mail

Send a letter with your written comments to the address in the contact information below.

All comments must be received by June 8, 2026.

Who is the focus of this consultation

We will engage with stakeholders who focus on public health and infectious diseases, including:

  • nurses
  • industry
  • academia
  • physicians
  • pharmacists
  • nurse practitioners
  • Indigenous partners
  • other health care professionals
  • public health agencies and departments

Key questions for discussion

We’re seeking your feedback on the proposed CAN-AWaRe classification.

When preparing your comments, please consider the following:

  • For each antibacterial listed, do you agree with Health Canada’s proposed classification?
    • If not, please indicate the alternative classification you recommend, based on the definitions provided for each respective category. Important: Provide your rationale and any supporting evidence.

We’re making the CAN-AWaRe classification available for the 60-day public consultation period. We will consider the comments gathered through the consultation when we finalize the classification.

Contact us

Pharmaceutical Drugs Directorate
Health Products and Food Branch
Address Locator: 0202B
Health Canada
Ottawa, ON, K1A 0K9
Email: amr-ram@hc-sc.gc.ca

Page details

From:

2026-04-09

Get daily alerts for Canada Health Canada Drug Announcements

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from Health Canada.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
Health Canada
Published
April 9th, 2026
Comment period closes
June 8th, 2026 (58 days)
Compliance deadline
June 8th, 2026 (58 days)
Instrument
Consultation
Legal weight
Non-binding
Stage
Consultation
Change scope
Substantive

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Public health authorities
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Antimicrobial drug classification Drug stewardship policy Public health consultation
Geographic scope
Canada CA

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Regulatory Affairs
Topics
Public Health Healthcare

Get alerts for this source

We'll email you when Canada Health Canada Drug Announcements publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!